L to R: George Werther, Bob Moses, Chris Belyea, Mark Diamond and Graham Mitchell
Robert Moses Chairman
Robert (Bob) W Moses is the Chairman of the company’s Board of Directors and is also Chairman of the Remuneration Committee and a member of the Audit Committee. Formerly Vice President of CSL Limited, Bob draws on more than 35 years experience in the pharmaceutical/biotechnology industry. During the period 1993-2001, Bob played a central role in CSL’s development internationally. Prior to joining CSL, Bob was Managing Director of commercial law firm Freehills, Chairman and CEO of a NASDAQ listed medical service company and Corporate Manager of New Business Development at ICI (now Orica). Bob also spent 17 years in various management roles at the multinational pharmaceutical company Eli Lilly. He is currently non-executive Chairman TGR Biosciences Pty Ltd, Sylvan Scientific Limited and a director for the CRC for Polymers.
Dr Chris Belyea Non-Executive Director
Chris Belyea, a non-executive director of the company, is Chairman of the Audit Committee and a member of the Remuneration Committee. Chris has a PhD in physics from the University of Melbourne and is a registered patent attorney. He became the founding CEO of Antisense Therapeutics in November 2000 and remained in this role until January 2002 (shortly after Antisense Therapeutics was listed on the Australian Stock Exchange). He worked for the Australian patent firm Griffith Hack & Co for 5 years before joining Circadian Technologies Limited as its Licensing and Projects Manager in 1996. In 1998 Dr Belyea became founding CEO and member of the board of Metabolic Pharmaceuticals Limited. He served with Metabolic as an executive until mid 2008 and now consults to companies on intellectual property and innovation practices. Mark Diamond Managing Director
Mark has over 20 years experience in the pharmaceutical and biotechnology industry. Before joining Antisense Therapeutics in 2001 as CEO, Mark was employed in the US as Director, Product Planning/Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding's European operation based in the UK and International Business Development Manager with Faulding in Australia. Mark has a BSc from Monash University Victoria and an MBA from Macquarie University in NSW.
Dr Graham Mitchell Non-Executive Director
Graham Mitchell is a non-executive director of the company and a member of its Remuneration Committee. He is an advisor in Innovation to the Victorian, Tasmanian & Northern Territory Governments, acts as Chief Scientist for the Department of Primary Industries and Department of Sustainability and Environment. Prof Mitchell is a non-executive director of Compumedics Limited, Avipep Pty Ltd, AgVic Services Pty Ltd, Adelaide Research & Innovation Pty Ltd and is a principal of Foursight Associates Pty Ltd. Dr Mitchell has held the position of Director of Research in the R&D Division of CSL Limited, non-executive Director of the Geoffrey Garndiner Dairy Foundation and for many years was a research scientist at the Walter & Eliza Hall Institute. Dr Mitchell is currently a non-executive director of Compumedics Limited.
Prof George Werther Non-Executive Director
George Werther is a non-executive director of the company and a member of its Remuneration and Audit Committees. George is Director of the Department of Endocrinology and Diabetes at the Royal Children's Hospital, and the Centre for Hormone Research at the hospital's Murdoch Childrens Research Institute, where he also serves on its Commercialisation Committee. He has served on many national and international scientific committees, and peer review bodies, and is on the editorial board of two international scientific journals. He was the Chairman of the Scientific Advisory Board for Neuren Pharmaceuticals and is a member of the Scientific Advisory Board of California-based Tercica Pharmaceuticals. He was on the council of the Australasian Paediatric Endocrine Group and was a board director of the Australia MedicAlert Foundation. He is also a Professorial Fellow at the University of Melbou
This Management group "WILL BRING HOME THE BACON"...Over the years they have had ups and downs but they are still one unit....this time they will create enormous shareholder wealth remembering they have been in talks with a Major Pharma pre AGM and pre Announcement...Mr Diamond confirmed that Talks re PHARMA "were still going very well!"
ANP Price at posting:
29.0¢ Sentiment: ST Buy Disclosure: Held
